Skip to main content
    A

    Abivax SA American Depositary Shares (ABVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $83.61
    -3.97 (-4.53%)

    Market Cap: $7.67B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Abivax SA American Depositary Shares (ABVX) Financials: Revenue, Profit and Cash Flow

    Updated Sep 21, 2026. Financial statements from company filings, amounts in EUR.

    Abivax SA American Depositary Shares reported revenue of EUR 0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was EUR -336.10M, operating cash flow was EUR -155.69M and free cash flow was EUR -155.83M. The quarter ended Jun 30, 2026 had revenue of EUR 0 and net income of EUR -117.43M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of EUR 246.06M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 20250-100.0%N/AN/AN/A
    Dec 202410.79M+133.5%100.0%-1602.9%-1633.1%
    Dec 20234.62M+0.8%99.0%-2756.5%-3197.1%
    Dec 20224.58M+12286.5%-1107.7%-1414.7%-1325.3%
    Dec 202137.00K-41.3%-123018.9%-111891.9%-114735.1%
    Dec 202063.00K+3050.0%-53623.8%-60330.2%-59604.8%
    Dec 20192.00K-88.9%-1409300.0%-1664800.0%-1531700.0%
    Dec 201818.00K+80.0%-85327.8%-106155.6%-87905.6%
    Dec 201710.00K-92.1%-144970.0%-141500.0%-112230.0%
    Dec 2016127.00KN/A-11431.5%-14359.1%-11266.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue010.79M4.62M4.58M37.00K63.00K2.00K18.00K10.00K127.00K
    Cost of revenue1.03MN/A707.00K50.76M45.52M33.78M28.19M15.38M14.51M14.64M
    Gross profit-1.03M10.79M4.57M-50.76M-45.52M-33.78M-28.19M-15.36M-14.50M-14.52M
    Research and development177.76M146.53M103.18M48.30M47.78M34.53M29.01M15.89M10.85M15.46M
    Operating income-246.06M-172.98M-127.38M-64.84M-41.40M-38.01M-33.30M-19.11M-14.15M-18.24M
    Net income-336.10M-176.24M-147.74M-60.74M-42.45M-37.55M-30.63M-15.82M-11.22M-14.31M
    EBITDAN/A-162.71MN/A-53.31M-38.59M-38.00M-33.22MN/A-13.98M-17.86M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Jun 2023
    Revenue00-2.02M02.02M07.40M03.39M02.33M2.25M
    Gross profitN/AN/A-3.05MN/A2.02MN/A7.40MN/A3.39MN/A2.33M2.25M
    Operating income-84.11M-56.23M-199.56M-80.71M-46.50M-47.20M-47.20M-50.19M-35.33M-44.67M-92.46M-39.53M
    Net income-117.43M-48.47M-287.69M-153.36M-48.41M-52.37M-52.37M-55.23M-38.77M-42.87M-95.79M-51.95M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of EUR 29.40M by 487.07M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets584.09M205.23M327.06M75.54M109.23M71.30M51.73M54.05M53.81M60.60M
    Current assets551.01M170.67M285.97M36.18M75.21M37.67M18.24M20.98M20.88M27.84M
    Cash and equivalents516.47M144.22M251.94M26.95M60.70M29.30M9.77M8.00M1.88M7.94M
    Total liabilities129.08M164.64M131.05M68.36M83.30M53.40M33.14M19.39M5.63M3.88M
    Short-term debt29.40M43.77M31.26M30.03M10.23M12.00K20.74M10.90M170.00K255.00K
    Long-term debtN/A52.16M44.70M36.58M53.45M28.45M20.74MN/AN/AN/A
    Shareholder equity455.01M40.58M196.01M7.19M25.93M17.90M18.59M34.66M48.18M56.72M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Jun 2024Dec 2023Jun 2023Mar 2023Dec 2022
    Total assets462.21M547.14M652.05M652.05M119.64M166.94M205.23M284.49M327.06M171.08MN/A75.54M
    Total liabilities95.94M117.55M140.81M140.81M167.92M173.53M164.64M158.02M131.05M90.59MN/A68.36M
    Cash and equivalents387.99M477.42M516.47M589.70M60.95M103.58M144.22M222.32M251.94M114.38MN/A26.95M
    Shareholder equity366.27M429.59M455.01M511.24M-48.28M-6.59M40.58M126.47M196.01M80.49MN/A7.19M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-155.69M-154.07M-100.01M-53.94M-45.05M-29.82M-27.47M-14.60M-8.45M-15.61M
    Capital expenditures136.40K643.00K265.00K323.00K47.00K898.00K941.00K763.00K979.00K721.00K
    Free cash flow-155.83M-154.72M-100.27M-54.26M-45.09M-30.72M-28.41M-15.37M-9.43M-16.33M
    Investing cash flow-13.18M15.76M-10.49M-12.03M-6.23M-575.00K-370.00K-254.00K-105.00K-94.00K
    Financing cash flow531.94M28.21M340.57M32.21M82.68M49.93M24.61M10.83M2.60M-438.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Jun 2023
    Operating cash flow-51.99M-50.52M-71.28M-71.28M-33.34M-33.28M-33.28M-35.38M-50.42M-34.75M-71.16M-27.60M
    Capital expenditures112.00K54.00K8.00K019.00K44.00K44.00K311.00K227.00K12.00K117.00K149.00K
    Free cash flow-52.10M-50.57M-71.29M-71.28M-33.36M-33.32M-33.32M-35.69M-50.65M-34.77M-71.28M-27.75M
    Last 12 quarters

    Frequently Asked Questions About ABVX

    What is Abivax SA American Depositary Shares' annual revenue?

    Abivax SA American Depositary Shares reported revenue of EUR 0 for the fiscal year ended Dec 31, 2025.

    How fast is Abivax SA American Depositary Shares' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Abivax SA American Depositary Shares profitable?

    No. Abivax SA American Depositary Shares reported net income of EUR -336.10M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does ABVX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -155.69M minus capital expenditures of EUR 136.40K produced free cash flow of EUR -155.83M.

    How much debt does Abivax SA American Depositary Shares have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of EUR 29.40M and cash and equivalents of EUR 516.47M.